<DOC>
	<DOCNO>NCT00209365</DOCNO>
	<brief_summary>The aim study explore contribution pollen starch granule induce symptom airway inflammation patient allergic rhinitis mild asthma control pollen exposure ( pollen challenge room Fraunhofer ITEM ) . Starch granule release pollen grain consider allergen carrier pollen . The hypothesis propose pollen starch granule important induction airway inflammation airway hyperresponsiveness .</brief_summary>
	<brief_title>The Role Pollen Starch Granules Pollen Challenge Studies Fraunhofer Environmental Exposure Unit</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>• Male female subject , age 1855 year . Women consider inclusion : Not pregnant nursing . Of nonchild bear potential ( i.e . physiologically incapable become pregnant , include female premenarchial postmenopausal document proof hysterectomy tubal ligation , meet clinical criterion menopause amenorrhoeic 1 year prior screen visit ) . Of childbearing potential use appropriate method contraception ( Oral contraceptive pill double barrier ) . Documented history bronchial asthma first diagnose least 6 month prior screen visit currently treat intermittent shortacting beta2agonist therapy inhalation . Patients low dose steroid wash 4 week . FEV1 &gt; 80 % predict screen . They history allergic rhinitis grass pollen positive skin prick test Dactylus glomerata pollen within 12 month prior screen visit . Documented sensitivity AMP provocative concentration AMP result 20 % fall FEV1 ( PC20 AMP ) &lt; 80mg/ml screen visit . Non smoker smoker history le 10 pack year . Able willing give write informed consent take part study . Available complete study measurement . • History respiratory tract infection and/or exacerbation asthma within 4 week inform consent study . Any history lifethreatening asthma , define asthma episode require intubation and/or associate hypercapnoea , respiratory arrest hypoxic seizure . Administration oral , injectable dermal corticosteroid within 8 week intranasal and/or inhaled corticosteroid within 4 week screen visit . Administration xanthine ( include theophylline , include caffeine ) , anticholinergic , cromoglycates and/or long act betaagonists within 1 week screen visit . Unable abstain medication include nonsteroidal antiinflammatory drug ( NSAIDS ) , antidepressant drug , antihistamine antiasthma , antirhinitis hay fever medication ( short act inhaled betaagonists ) paracetamol ( 1g paracetamol per day permit treatment minor ailment e.g . headache ) 1 week prior screen throughout course study . Past present disease , judge investigator , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease , haematological disease , neurological disease , endocrine disease pulmonary disease ( include confine chronic bronchitis , emphysema , tuberculosis , bronchiectasis cystic fibrosis ) . History MI CVA specific contraindication AHR test Known suspect hypersensitivity adverse reaction AMP Subject undergo allergen desensitisation therapy There risk noncompliance study procedure Neurological psychiatric disease history drug alcohol abuse would interfere subject 's proper completion protocol assignment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>